Scarica l'app Stockscreener
4.05
2.27%
0.09
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
XTX Topco Ltd Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding - Simply Wall St
Fmr LLC Grows Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - AccessWire
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Drops By 5.2% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - AccessWire
Progressive Supranuclear Palsy Market Statistics Expected - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - AccessWire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Amylyx stock receives Buy rating from H.C. Wainwright, set for Phase 3 trial significance - Investing.com
4 Analysts Assess Amylyx Pharma: What You Need To Know - Inkl
Amylyx announces design of LUCIDITY clinical trial - Yahoo Finance
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia - Business Wire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Walleye Capital LLC - MarketBeat
Amylyx Pharmaceuticals chief medical officer sells $30,007 in stock By Investing.com - Investing.com Australia
Amylyx Pharmaceuticals chief medical officer sells $30,007 in stock - Investing.com
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
Alpha Wave Global LP Invests $2.17 Million in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
PTC halts development of ALS drug after trial miss - The Pharma Letter
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along - Seeking Alpha
Connor Clark & Lunn Investment Management Ltd. Has $2.85 Million Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise - MSN
Goldman Sachs reiterates Neutral on Amylyx stock, target unchanged amid PBH market uncertainties - Investing.com Nigeria
Baird R W Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) to Strong-Buy - MarketBeat
Baird Upgrades Amylyx Pharmaceuticals (AMLX) - MSN
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha
Robert W. Baird Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) to "Outperform" - MarketBeat
Amylyx shares rise to Outperform rating as Baird projects strong PBH drug market impact - Investing.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Yahoo Finance
Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $12.00 Price Target at HC Wainwright - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Q3 2024 Financial Highlights - TipRanks
Amylyx Pharmaceuticals Inc. (AMLX) Quarterly 10-Q Report - Quartz
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):